Overview

A Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Status:
Not yet recruiting

Trial end date:
2024-04-30

Target enrollment:

Participant gender:

Summary

The purpose of this prospective study is to assess the safety and efficacy of everolimus in Taiwanese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC). Only patients who fulfil the local reimbursement criteria of everolimus for TSC-AML will be included in this study.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Everolimus